Upstream Bio, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses), averaging +1.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.78 | $-0.73 | +6.4% | Beat | |
| Q1 FY26 | $-0.80 | $-0.75 | +6.3% | Beat | |
| Q4 FY25 | $-0.73 | $-0.79 | -8.2% | Miss |
Back to UPB overview · UPB holders · UPB KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.